Extended indication Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, an
Therapeutic value No estimate possible yet
Total cost 156,150,000.00
Registration phase Registration application pending

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Breast cancer
Extended indication Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with locally advanced, inflammatory, or earlystage triple-negative breast cancer at high-risk of recurrence.
Proprietary name Keytruda
Manufacturer MSD
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Infusion fluid
Budgetting framework Intermural (MSZ)
Additional comments Anti-PD-1

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date August 2021
Expected Registration March 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times every 3 weeks
Dosage per administration 200 mg
References NCT02819518
Additional comments Maximaal 1 jaar behandeling. Nota bene: voor mono en combinatie therapie ook 1 x 400mg per 6 weken mogelijk.

Expected patient volume per year

Patient volume

< 1,735

Market share is generally not included unless otherwise stated.

References NKR
Additional comments NKR 2018: 1.735 diagnoses mammacarcinoom HR-, HER- waarbij een chirurgische ingreep is gedaan.

Expected cost per patient per year

Cost < 90,000.00
References G-Standaard
Additional comments AIP per november 2017: €2.624,38 per injectieflacon 25mg/ml flacon 4ml (oplossing). Uitgaande van een behandeling van 1 x per 3 weken 200mg voor 12 maanden zou dat gaan om maximaal €90.000 per patiënt per jaar. De behandelduur die voor deze indicatie onderzocht wordt is maximaal 12 maanden. Voor pembrolizumab is een financieel arrangement van toepassing tot 1 januari 2024. Aankomende indicatie uitbreidingen vallen onder deze overeenkomst, mits zij voldoen aan stand der wetenschap en praktijk.

Potential total cost per year

Total cost

156,150,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No
References Fabrikant

Indication extension

Indication extension Yes
Indication extensions Indicatie uitbreidingen worden weergegeven in de Horizonscan Geneesmiddelen (maagkanker, hoofd- en halskanker, huidkanker, longkanker, nierkanker, et cetera)
References Fabrikant

Other information

There is currently no futher information available.